Arcus files preliminary prospectus supplement, cites new casdatifan ccRCC data
Arcus proposed a common stock offering through underwriters Jefferies, Leerink Partners and TD Cowen, pointing to casdatifan results and an estimated $694.0 million cash balance.
Arcus Biosciences filed a preliminary prospectus supplement with the SEC on October 21, 2026, for a proposed offering of common stock. The filing states it is not complete and may be changed, and is not an offer to sell these securities or a solicitation of an offer to buy them in any jurisdiction where such offer or sale is not permitted.1 The number of shares and price were left blank in the filing. The company's stock trades on the New York Stock Exchange under the symbol "RCUS," and on October 20, 2026, the last reported sale price was $23.75 per share.1 Underwriters named are Jefferies, Leerink Partners and TD Cowen.1
The filing cites preliminary financial information: based upon preliminary estimates and information available to the company as of October 21, 2026, Arcus estimates it had approximately $694.0 million in cash, cash equivalents and marketable securities as of September 30, 2026.1 The company said it intends to use net proceeds from the offering to fund ongoing research and development activities, including the expansion and acceleration of its clinical development program for casdatifan, and for other general corporate purposes, including working capital and operating expenses.1
The filing also references new clinical data Arcus presented on October 20, 2026, from its ARC-20 platform study of casdatifan in clear cell renal cell carcinoma, with a data cutoff of September 4, 2026. In the first-line, TKI-free setting, casdatifan plus anti-PD-1 zimberelimab in 30 patients showed, with 11.5 months of median follow up, landmark progression-free survival of 86% and 69% at six and 12 months, respectively, a confirmed objective response rate of 50%, and a primary progression rate of 6.7%.1
In the second-line setting, casdatifan plus cabozantinib in 43 patients, with 21.3 months of median follow up, produced median progression-free survival of 14.5 months, 18-month landmark overall survival of 77%, a confirmed objective response rate of 44% and primary progression of 5%.1 For late-line monotherapy, casdatifan across 121 patients in four pooled cohorts, with 28 months of median follow up, showed median overall survival of 35 months, median progression-free survival of 13 months and a confirmed objective response rate of 36%.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.